Systemic therapy in melanoma

Seminars in Surgical Oncology

Volumn 14, Issue 4, 1998, Pages 319-327

  Nathan, Faith E ^a,b   Mastrangelo, Michael J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Carmustine; Cisplatin; Clinical trials; Combined antineoplastic agents; Dacarbazine; Interferons; Interleukin 2; Melanoma; Neoplasm metastases; Nit rosourea compounds; Paclitaxel; Phytogenic antineoplastic agents; Tamoxifen; Vinblastine; Vincristine

Indexed keywords

ALPHA INTERFERON; AMIFOSTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTARABINE; DACARBAZINE; FOTEMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 2; LOMUSTINE; PACLITAXEL; TAMOXIFEN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MELANOMA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; INTERFERONS; INTERLEUKIN-2; MELANOMA; SKIN NEOPLASMS;

EID: 0031919420     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199806)14:4<319::AID-SSU8>3.0.CO;2-5     Document Type: Review

References (104)

1. Nathan FE, Berd D, Mastrangelo MJ: Chemotherapy of melanoma. In Perry MC (ed): "The chemotherapy source book." 2nd ed. Baltimore: Williams and Wilkins; 1996, p. 1043-1069.
2. Bellett RE, Mastrangelo MJ, Laucius JF, Bodurtha AJ: Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat Rep 1976; 60:595-600.
3. Czarnetzki BM, Macher E: DTIC (dacarbazine) induced hepatic damage. Arch Dermatol Res 1981; 270:375-376.
4. McClay E, Lusch CJ, Mastrangelo MJ: Allergy-induced hepatic toxicity associated with dacarbazine [letter]. Cancer Treat Rep 1987; 71:219-220.
5. Ceci G, Balla M, Melissari M, et al.: Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer 1988; 61:1988-1991.
6. Jacquillat C, Khayat D, Banzet P, et al.: Final report of the French Multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66:1873-1878.
7. Falkson CI, Falkson G, Falkson HC: Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest New Drugs 1994; 12:251-254.
8. Camacho FJ, Young CW, Wittes RE: Phase II trial of vindesine in patients with malignant melanoma. Cancer Treat Rep 1980; 64:179-181.
9. Retsas S, Newton KA, Westbury G: Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol 1979; 2:257-260.
10. Smith IE, Hedley DW, Powles TJ, McElwain TJ: Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma and other solid tumors. Cancer Treat Rep 1978; 62:1427-1433.
11. Quagliana JM, Stephens RL, Baker LH, Costanzi JJ: Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1984; 2:316-319.
12. Carmichael J, Atkinson RJ, Calman KC, et al.: A multicentre phase II trial of vindesine in malignant melanoma. Eur J Cancer Clin Oncol 1982; 18:1293-1295.
13. Nelimark RA, Peterson BA, Vosika GJ, Conroy JA: Vindesine for metastatic malignant melanoma. A phase II trial. Am J Clin Oncol 1983; 6:561-564.
14. Rumke P, Everall JD, Mulder JH, et al.: EORTC phase II trial of vindesine in advanced melanoma. Eur J Cancer Clin Oncol 1983; 19:1173-1174.
15. Arseneau JC, Mellette SJ, Kuperminc M, Wolter J: Phase II study of vindesine in metastatic malignant melanoma [letter]. Cancer Treat Rep 1981; 65:355-356.
16. Wagstaff J, Anderson HA, Shiu W, Thatcher N: Phase II study of vindesine infusion in visceral metastatic malignant melanoma. Cancer Treat Rep 1983; 67:839-840.
17. Mayol XF, Beltran J, Rubio-Bazan R, et al.: Multicenter phase II trial with 5 day continuous infusion vindesine in metastatic malignant melanoma. Cancer Treat Rep 1984; 6:1199-1200.
18. DiBella NJ, Berris R, Garfield D, et al.: Vindesine in advanced breast cancer, lymphoma and melanoma. A Colorado Clinical Oncology Group study. Invest New Drugs 1984; 2:323-328.
19. Scheff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77:1561-1565.
20. Wiernik PH, Einzig AI: Taxol m malignant melanoma. Monogr Natl Cancer Inst 1993; 15:185-187.
21. Wiernik PH, Schwartz EL, Einzig A, et al.: Phase I trial of Taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5:1232-1239.
22. Einzig A, Trump DL, Sasloff J. Phase II pilot study of Taxol in patients with malignant melanoma [Abstract]. Proc Am Soc Clin Oncol 1988; 7:249.
23. Aamdal S, Wolff I, Kaplan S, et al.: Docetaxel (taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A:1061-1064.
24. Bleehen NM, Newlands ES, Lee SM, et al.: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13:910-913.
25. Pisha E, Chai H, Lee IS, et al.: Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nature Med 1995; 1:1046-1051.
26. Avril MF, Bonneterre J, Delaunay M, et al.: Combination chemotherapy of dacarbazine and fotemustine is disseminated malignant melanoma: experience of the French Study Group. Cancer Chemother Pharmacol 1990; 27:81-84.
27. Avril MF, Bonneterre J, Cupissol D, et al.: Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992; 28A:1807-1811.
28. Binder M, Winkler A, Dorffner R, et al.: Fotemustine plus dacarbazine in advanced stase III malignant melanoma. Eur J Cancer 1992; 28A:1814-1816.
29. Aamdal S, Gerard B, Bohman T, D'Incalci M: Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma-an effective combination with unexpected toxicity. Eur J Cancer 1992; 28:447-450.
30. Del Prete SA, Maurer LH, O'Donnell J, et al.: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68:1403-1405.
31. McClay EF, Mastrangelo MJ, Bellet RE, Berd D: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987; 71:465-469.
32. Lattanzi SC, Tosteson T, Chertoff J, et al.: Dacarbazine, cisplatin and carmustine with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995; 5:365-369.
33. Berd D, Mastrangelo MJ: Combination chemotherapy of metastatic melanoma [letter]. J Clin Oncol 1995; 13:796.
34. McClay EF, Mastrangelo MJ, Berd D, Bellet RE: Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50:553-556.
35. Fierro MT, Bertero M, Novelli M, et al.: Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res 1993; 3:127-131.
36. Reintgen D, Saba H: Chemotherapy for stage 4 melanoma: a three-year experience with cisplatin, DTIC, BCNU, and tamoxifen. Semin Surg Oncol 1993; 9:251-255.
37. Crowell EB Jr, Higa GM: The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen. W V Med J 1993; 89:233-235.
38. Richards JM, Gilewski TA, Ramming K, et al.: Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 1992; 69:427-429.
39. Foshag LJ, Morton DL, Nizze JA, Chawla SP: Response to chemotherapy in melanoma patients after active specific immunotherapy (ASI) with melanoma cell vaccine (MCV)[Abstract]. Proc Am Soc Clin Oncol 1993; 12:396.
40. Adlakha A, Robinson WA, Gonzalez R, et al.: Combination chemotherapy and tamoxifen in the treatment of disseminated malignant melanoma [Abstract]. Proc Second Int Conf Mel Venice, Italy Oct. 16-19, 1989; 40.
41. Rusthoven J, Quirt I, Iscoe N, et al.: A randomized placebo-controlled trial comparing BCNU (B), dacarbazine (D), and cisplatin (P) versus BDP and high-dose tamoxifen in the treatment of metastatic melanoma [Abstract]. Proc Am Soc Clin Oncol 1995; 14:413.
42. Margolin K, Liu PY, Flaherty L, et al.: Low antitumor activity of BCNU, DTIC, cisplatin (DDP) and tamoxifen (TAM) in advanced melanoma: a Southwest Oncology Group study [Abstract]. Proc Am Soc Clin Oncol 1997; 16:495.
43. Johnston SR, Constenia DO, Moore J, et al.: Randomised phase II trial of BCDT (BCNU, cisplatin, dacarbazine and tamoxifen) with or without interferon alpha and interteukin-2 (IL-2) in patients with metastatic melanoma [Abstract]. Proc Am Soc Clin Oncol 1997; 16:490.
44. ® melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma [Abstract]. Proc Am Soc Clin Oncol 1997; 16:494.
45. Cocconi G, Bella M, Calabresi F, et al.: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327:516-523.
46. Hofmann J, Fiebig HH, Winterhalter BR, et al.: Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int J Cancer 1990; 45:536-539.
47. McClay EF, McClay ME, Albright KD, et al.: Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma: a biologically important observation. Cancer 1993; 72:1914-1918.
48. Sileni VC, Nortilli R, Medici M, et al.: BCNU (B), cisplatin (C), dacarbazine (D) and tamoxifen (T)(BCDT) m metastatic melanoma (MM): results of a randomized phase II study [Abstract]. Proc Am Soc Clin Oncol 1997; 16:495.
49. Cohen SM, Ohnuma T, Ambinder EP, Holland JF: Lomustine, bleomycin, and cisplatin in patients with metastatic malignant melanoma. Cancer Treat Rep 1986; 70:688-689.
50. Grossman SA, Wharam M, Sheidler V, et al.: BCNU/cisplatin (B/C) followed by radiation in poor prognosis patients with high grade astrocytomas (GGA)[Abstract]. Proc Am Soc Clin Oncol 1992; 11:149.
51. Gilbert MR, Lunsford LD, Konziolka D, et al.: A phase II trial of continuous infusion chemotherapy, external beam radiotherapy and local boost radiotherapy for malignant melanoma [Abstract]. Proc Am Soc Clin Oncol 1993; 12:176.
52. D'Incalci M, Citti L, Taverna P, Catapano CV: Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 1988; 15:279-292.
53. Gerard B, Aamdal S, Lee SM, et al.: Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine - in patients with melanoma. Eur J Cancer 1993; 29A:711-719.
54. Creagan ET, Ahmann DL, Frytak S, et al.: Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analysis. Cancer 1987; 59:638-646.
55. Hersey P, Hasic E, MacDonald M, et al.: Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer 1985; 51:815-826.
56. Legha SS, Papadopoulos NE, Plager C, et al.: Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules [published erratum appears in J Clin Oncol 1987; 5:1858]. J Clin Oncol 1987; 5:1240-1246.
57. Kuzmits R, Kokoschka EM, Micksche M, et al.: Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma. Oncology 1985; 42(Suppl 1):26-32.
58. Elsasser-Beile U, Drees N, Neumann HA, Schopf E: Phase II trial of recombinant leukocyte a interferon in advanced malignant melanoma. J Cancer Res Clin Oncol 1987; 113:273-278.
59. Krown SE, Burk MW, Kirkwood JM, et al.: Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep 1984; 68:723-726.
60. Landthaler M, Geyer C, Papendick U, Braun-Falco O: [Alpha 2-interferon therapy in metastasizing malignant melanoma]. Dtsch Med Wochenschr 1987; 112:919-921. (Ger).
61. Kirkwood JM, Ernstoff MS, Davis CA, et al.: Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103:32-36.
62. Coates A, Rallings M, Hersey P, Swanson C: Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res 1986; 6:1-4.
63. Dorval T, Palangie T, Jouve M, et al.: Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma. Cancer 1986; 58:215-218.
64. Dorval T, Palangie T, Jouve M, et al.: Treatment of metastatic malisnant melanoma with recombinant interferon alfa-2b. Invest New Drugs 1987; 5 Suppl:S61-3.
65. Mughal TI, Robinson WA, Thomas MR, Spiegel RJ: Role of reconibmant interferon alpha-2 in treatment of advanced malignant melanoma [Abstract]. Proc Am Soc Clin Oncol 1988; 7:250.
66. von Wussow P, Block B, Hartmann F, Deicher H: Intralesional interferon-alpha therapy m advanced malignant melanoma. Cancer 1988; 61:1071-1074.
67. Haase KD, Lange OF, Scheef W: Interferon-gamma treatment of metastasized malignant melanoma. Anticancer Res 1987; 7:335-336.
68. Creagan ET, Ahmann DL, Long HJ, et al.: Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma. Cancer Treat Rep 1987; 71:843-844.
69. Ernstoff MS, Trautman T, Davis CA, et al.: A randomized phase I/ II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol 1987; 5:1804-1810.
70. Atkins MB, Lotze M, Wiernik P, et al.: High-dose IL-2 therapy alone results in long-term durable complete responses in patients with metastatic melanoma [Abstract]. Proc Am Soc Clin Oncol 1997; 16:494.
71. Siegel JP, Puri RK: Interleukin-2 toxicity [Review]. J Clin Oncol 1991; 9:694-704.
72. West WH, Tauer KW, Yannelli JR, et al.: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905.
73. Legha SS, Gianan MA, Plager C, et al.: Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996; 77:89-96.
74. Sparano JA, Fisher RI, Sunderland M, et al.: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11:1969-1977.
75. Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ: Effects of anticancer drugs on the immune system in humans. [Review]. Semin Oncol 1989; 16:230-253.
76. Dummer R, Gore ME, Hancock BW, et al.: A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Cancer 1995; 75:1938-1044.
77. Flaherty LE, Robinson WI, Redman BG, et al.: A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993; 71:3520-3525.
78. West W, Tauer K, Barth N, et al.: Adoptive immunotherapy and sequential DTIC chemotherapy m metastatic melanoma [Abstract]. Proc Am Soc Clin Oncol 1989; 8:281.
79. Atkins M, Demchak P, Mier J, et al.: Phase II study of alternating interleukin-2 (IL2) and cisplatin (cis DDP) with WR-2721 in metastatic melanoma [Abstract]. Proc Am Soc Clin Oncol 1989; 8:287.
80. Seigler HF, Lucas VS, Pickett NJ, Huang AT: DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 1980; 46:2346-2348.
81. York RM, Foltz AT: Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 1988; 61:2183-2186.
82. Young DW, Lever RS, English JS, MacKie RM: The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. Cancer 1985; 55:1879-1881.
83. Zacharias PM, The Prudente Foundation Melanoma Study Group: Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU and DTIC (BOLD regimen). Cancer 1989; 63:1676-1680.
84. Jose DG, Minty CCJ, Hillcoat BL: Treatment of patients with disseminated malignant melanoma with bleomycin, oncovin, lomustine and DTIC (BOLD)[Abstract]. Proc First Int Conf Skin Mel Venice, Italy, May 6-9, 1985; 1:151.
85. Ceschia T, Cartei G, Clocchiatti L, et al.: BELD polychemotherapy in advanced melanoma [Abstract]. Proc Second Int Conf Mel 1989; 2:412.
86. Pyrhonen S, Hahka-Kemppinen M, Muhonen T: A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10:1919-1926.
87. Nathan FE, Berd D, Sato T, et al.: BOLD + interferon in the treatment of metastatic uveal melanoma: First report of active systemic therapy. J Exp Clin Cancer Res 1997; 16:201-208.
88. LoRusso PM, Polin L, Ackerman SL, et al.: Antitumor efficacy of interleukin-2 alone and combination with chemotherapeutic agents in murine syngeneic solid tumor systems [Abstract]. Proc Am Assoc Cancer Res 1989; 30:614.
89. Richards JM, Ramming K, Bitram NM, et al.: Combination of chemotherapy and biological therapy for the treatment of melanoma [Abstract]. Clin Res 1990; 38:844A.
90. Richards JM, Mehta N, Ramming K, Skosey P: Sequential chemoimmunotherapy m the treatment of metastatic melanoma. J Clin Oncol 1992; 10:1338-1343.
91. Legha S, Ring S, Eton O, et al.: Durable complete responses (CRs) in metastatic melanoma treated with biochemotherapy using cisplatin + vinblastine + DTIC + (CVD) and IL-2 + interferon-alpha (IFN-α)[Abstract]. Proc Am Soc Clin Oncol 1995; 14:412.
92. Legha SS: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy [Review]. Semin Oncol 1997; 24(I Suppl 4):S39-43.
93. O'Day SJ, Boasberg P, Guo M, et al.: Phase II trial of concurrent biochemotherapy (c-BC) with decrescendo interleukin-2 (d-Il-2), tamoxifen (T), and G-CSF support in patients with metastatic melanoma (MM)[Abstract]. Proc Am Soc Clin Oncol 1997; 16:490a.
94. McDermott DF, Mier JW, Lawrence DP, et al.: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), interleukin-2 (IL-2) and interferon alpha-2b (IFN) in patients with metastatic melanoma [Abstract]. Proc Am Soc Clin Oncol 1997; 16:490.
95. Frei E 3rd, Canellos GP: Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69:585-594.
96. Antman K, Eder JP, Elias A, et al.: High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 1987; 71:119-125.
97. Phillips GL, Fay JW, Herzig GP, et al.: Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC:4366650 and cryo-preserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 1983; 52:1792-1802.
98. Slease RB, Benear JB, Selby GB, et al.: High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol 1988; 6:1314-1320.
99. Thatcher D, Lind M, Morgenstern G, et al.: High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer 1989; 63:1296-1302.
100. Peters WP, Kurtzbers J, Atwater S, et al.: Comparative effects of rHuG-CSF and rHuGM-CSF on hematopoietic reconstitution and granulocyte function following high dose chemotherapy and autologous bone marrow transplantation (ABMT)[Abstract]. Proc Am Soc Clin Oncol 1989; 8:181.
101. Tchekmedyian NS, Tait N, Van Echo D, Aisner J: High-dose chemotherapy without autologous bone marrow transplantation in melanoma. J Clin Oncol 1986; 4:1811-1818.
102. Portlock C, Murren J, Buzaid A, et al.: High dose cisplatin (C) and dacarbazine (D) in metastatic melanoma [Abstract]. Proc Am Soc Clin Oncol 1989; 8:284.
103. Glover D, Glick JH, Weiler C, et al.: WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5:574-578.
104. Glover D, Glick J, Weiler C, et al.: High dose cis-platinum (DDP) and WR-2721 (WR) in metastatic melanoma [Abstract]. Proc Am Soc Clin Oncol 1988; 7:247.